<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04628481</url>
  </required_header>
  <id_info>
    <org_study_id>LDX0319</org_study_id>
    <secondary_id>2020-001926-71</secondary_id>
    <nct_id>NCT04628481</nct_id>
  </id_info>
  <brief_title>A Study of Oral Ladarixin in New-onset Type 1 Diabetes and a Low Residual β-cell Function</brief_title>
  <official_title>Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess Efficacy - Safety of 400 mg Twice a Day Oral Ladarixin in Pts With New-onset Type 1 Diabetes and Low Residual β-cell Function at Baseline (GLADIATOR STUDY)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dompé Farmaceutici S.p.A</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dompé Farmaceutici S.p.A</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this clinical trial is to assess whether ladarixin treatment is effective in&#xD;
      preserving beta-cell function and delaying the progression of type 1 diabetes (T1D) in&#xD;
      adolescent and adult patients. The safety of ladarixin in the specific clinical setting will&#xD;
      be also evaluated.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase 3, multicenter, double-blind, placebo-controlled study. It has been designed&#xD;
      to further evaluate whether ladarixin is effective in preserving beta-cell function and&#xD;
      slowing-down the progression of T1D) in patients with a more severe disease presentation.&#xD;
&#xD;
      The study is planned to be performed at about 40 study centers in EU, US and in other&#xD;
      countries, if appropriated. At each study center, the Principal Investigator (PI) will be&#xD;
      responsible for ensuring that the investigation is conducted according to the signed&#xD;
      Investigator agreement, the protocol, GCP guidelines, and local regulations.&#xD;
&#xD;
      The study is planned to involve -327 patients with new-onset T1D, to include about 200&#xD;
      adolescents (14-17 years). Patients will be randomly (2:1) assigned to receive either&#xD;
      ladarixin treatment (400 mg b.i.d. for 13 cycles of 14 days on/14 days off - treatment group)&#xD;
      or matched placebo (control group). The two groups will be balanced within centers.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 21, 2020</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients will be randomly (2:1) assigned to receive either ladarixin treatment (400 mg b.i.d. for 13 cycles of 14 days on/14 days off - treatment group) or matched placebo (control group). The two groups will be balanced within centers.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>The study will proceed under double-blind condition up to month 18 visit of the last patient randomized. Thereafter, the blind will be broken and remaining follow-up will proceed in an open fashion. This approach will allow to anticipate access to efficacy data without significantly affecting data integrity.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in 2-hour AUC of C-peptide response to the Mixed Model Tolerance Test (MMTT)</measure>
    <time_frame>Month 12</time_frame>
    <description>C-peptide level is an indirect measure of pancreatic beta-cell function. The MMTT was performed after an overnight fast, at baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in HbA1c</measure>
    <time_frame>Month 12</time_frame>
    <description>HbA1c measurement can be used as a diagnostic test for diabetes providing that stringent quality assurance tests are in place and assays are standardised to criteria aligned to the international reference values, and there are no conditions present which preclude its accurate measurement.&#xD;
An HbA1c of 6.5% is recommended as the cut point for diagnosing diabetes. A value of less than 6.5% does not exclude diabetes diagnosed using glucose tests.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in 2-hour AUC of C-peptide response to the MMTT</measure>
    <time_frame>Months 6, 18 and 24</time_frame>
    <description>C-peptide level is an indirect measure of pancreatic beta-cell function. The MMTT was performed after an overnight fast, at baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HbA1c from baseline</measure>
    <time_frame>Months 6, 18 and 24</time_frame>
    <description>HbA1c measurement can be used as a diagnostic test for diabetes providing that stringent quality assurance tests are in place and assays are standardised to criteria aligned to the international reference values, and there are no conditions present which preclude its accurate measurement. An HbA1c of 6.5% is recommended as the cut point for diagnosing diabetes. A value of less than 6.5% does not exclude diabetes diagnosed using glucose tests.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time in range (TIR) by Continuous Glucose Monitoring (CGM)</measure>
    <time_frame>Months 6, 12, 18, 24</time_frame>
    <description>Continuous glucose monitors (CGM) continually monitors glucose plasma levels through an external device that's attached to the body, and gives real-time updates.Time in range is the amount of time the patient spends in the target blood sugar (blood glucose) range-between 70 and 180 mg/dL for most people.&#xD;
The time in range method works with the individual CGM's data by looking at the amount of time blood sugar has been in target range and the times it has been high (hyperglycemia) or low (hypoglycemia).&#xD;
This data is helpful in finding out which types of foods and what activity level causes patient's blood sugar to rise and fall.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with HbA1c &lt;7% who did not experience severe hypoglycemic events during treatment</measure>
    <time_frame>Months 6, 12, 18, 24</time_frame>
    <description>For the purpose of this study, a severe hypoglycemic event is defined as an event with one of the following symptoms: &quot;memory loss, confusion, uncontrollable behavior, irrational behavior, unusual difficulty in awakening, suspected seizure, seizure, loss of consciousness, or visual symptoms&quot;, in which the subject was unable to treat him/herself and which was associated with either a blood glucose level &lt;54mg/dL or prompt recovery after oral carbohydrate, i.e. glucose, or glucagon administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average (previous 3 days) daily insulin requirement (IU/kg/day)</measure>
    <time_frame>Months 6, 12, 18, 24</time_frame>
    <description>For the purpose of this study, daily insulin is averaged over the previous 3 days.Insulin requirement (IU/kg/day averaged over the previous 3 days) was to be recorded to Months 6, 12, 18 and 24.&#xD;
Patients were admitted to intensive diabetes management, according to current ADA recommendation [2014]. Patients were instructed to self-monitor their glucose values at least 4 times a day and to report (glucose meter/log) outcome to the diabetes management team. Insulin intake was adjusted to target HbA1c levels of less than 7% and self-monitored (fingerstick):&#xD;
pre-prandial blood glucose of 70-130 mg/dL&#xD;
post-prandial blood glucose &lt; 180 mg/dL&#xD;
bed-time blood glucose of 110-150 mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with HbA1c &lt;7% and daily insulin requirement &lt;0.5 (IU/kg/day)</measure>
    <time_frame>Months 6, 12, 18, 24</time_frame>
    <description>The sample size of the study is calculated on the &quot;proportion of patients with a HbA1c &lt; 7% and daily insulin requirement &lt;0.50 IU/Kg/day&quot;, a post-hoc composite endpoint derived from data of the phase 2 trial (MEX0114), considering a larger effect size expected from the longer treatment length (one year versus 3 months). Follow-up is extended up to 24 months to evaluate the potential persistency of any glycemic benefit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of self-reported episodes of severe hypoglycemia</measure>
    <time_frame>Months 6, 12, 18, 24</time_frame>
    <description>For the purpose of this study, a severe hypoglycemic event is defined as an event with one of the following symptoms: &quot;memory loss, confusion, uncontrollable behavior, irrational behavior, unusual difficulty in awakening, suspected seizure, seizure, loss of consciousness, or visual symptoms&quot;, in which the subject was unable to treat him/herself and which was associated with either a blood glucose level &lt;54mg/dL or prompt recovery after oral carbohydrate, i.e. glucose, or glucagon administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients not requiring insulin therapy</measure>
    <time_frame>Months 6, 12, 18, 24</time_frame>
    <description>This outcome aims to assess the % of patients who do not require an insulin therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated Glucose Disposal Rate (eGDR)</measure>
    <time_frame>Months 6, 12, 18, 24</time_frame>
    <description>Estimated Glucose Disposal Rate (eGDR) is a marker for the Assessment of Insulin Resistance and a validated clinical tool for estimating insulin sensitivity in type 1 diabetes.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">327</enrollment>
  <condition>New-onset type1 Diabetes</condition>
  <arm_group>
    <arm_group_label>Ladarixin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>400 mg b.i.d. for 13 cycles of 14 days on/14 days off</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>matching placebo b.i.d. for 13 cycles of 14 days on/14 days off</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ladarixin</intervention_name>
    <description>Oral ladarixin twice a day for 13 cycles</description>
    <arm_group_label>Ladarixin</arm_group_label>
    <other_name>allosteric inhibitor of CXCL8 (IL-8), CXCR1 and CXCR2 receptors</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral placebo twice a day for 13 cycles</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male and female patients aged 14-45 years, inclusive;&#xD;
&#xD;
          2. New-onset T1D (1st IMP dose within 100 days from 1st insulin administration);&#xD;
&#xD;
          3. Positive for at least one diabetes-related auto-antibody (anti-GAD; IAA, if obtained&#xD;
             within 10 days of the onset of insulin therapy; IA-2 antibody; ZnT8);&#xD;
&#xD;
          4. Require, or has required at some time, insulin therapy through multiple daily&#xD;
             injections (MDI) or Continuous Subcutaneous Insulin Infusion (CSII).&#xD;
&#xD;
          5. Fasting C peptide &lt; 0.205nmol/L;&#xD;
&#xD;
          6. Residual beta-cell function as per peak stimulated (MMTT) C-peptide level &gt;0.2nmol/L;&#xD;
             MMTT should not be performed within one week of resolution of a diabetic ketoacidosis&#xD;
             event;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any other chronic disease, including type 2 diabetes, apart from autoimmune&#xD;
             hypothyroidism requiring thyroid hormone replacement only; patients with severe&#xD;
             (myxedema) disease potentially requiring immunosuppressive therapy will be excluded;&#xD;
&#xD;
          2. Moderate to severe renal impairment as per estimated Glomerular Filtration Rate (eGFR)&#xD;
             60 mL/min/1.73m2, as determined using Chronic Kidney Disease Epidemiology&#xD;
             Collaboration (CKD-EPI) creatinine equation (see Appendix 14.4.3);&#xD;
&#xD;
          3. Hepatic dysfunction defined by increased ALT/AST &gt; 3 x upper limit of normal (ULN) and&#xD;
             increased total bilirubin &gt; 3 mg/dL [&gt;51.3 μmol/L];&#xD;
&#xD;
          4. Hypoalbuminemia defined as serum albumin &lt; 3 g/dL;&#xD;
&#xD;
          5. QTcF &gt; 470 msec;&#xD;
&#xD;
          6. Occurrence of an episode of ketoacidosis or hypoglycemic coma in the past 2 weeks;&#xD;
&#xD;
          7. A history of significant cardiovascular disease/abnormality;&#xD;
&#xD;
          8. Known hypersensitivity to non-steroidal anti-inflammatory drugs;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Annarita Maurizi, MD</last_name>
    <role>Study Director</role>
    <affiliation>Dompé Farmaceutici</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Flavio Mantelli, MD</last_name>
    <phone>+39 583831</phone>
    <email>info@dompe.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Annarita Maurizi, MD</last_name>
    <phone>+39 583831</phone>
    <email>info@dompe.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama at Birmingham (UAB) - The Kirklin Clinic (TKC) - Multidisciplinary Comprehensive Diabetes Clinic (MCDC)</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fernando Ovalle</last_name>
      <email>fovalle@uab.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Phoenician Centers for Research and Innovation</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kenneth Boren, MD</last_name>
      <email>kenboren@cox.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jeremy Pettus</last_name>
      <email>jpettus@ucsd.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Center of Excellence in Diabetes &amp; Endocrinology (CEDE)</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95821-2123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gnanagurudasan Prakasam, MD</last_name>
      <email>prakasg@sutterhealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Colorado School of Medicine - Barbara Davis Center for Childhood Diabetes (BDC) - Specialty Clinic</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Steck</last_name>
      <email>andrea.steck@cuanschutz.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Christiana Care Endocrinology Specialists</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19713</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Lenhard, MD</last_name>
      <email>jlenhard@christianacare.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Diabetes Care Center - Hudson</name>
      <address>
        <city>Hudson</city>
        <state>Florida</state>
        <zip>34667-7151</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jesus Penabad, MD</last_name>
      <email>JPENABA1@TAMPABAY.RR.COM</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Global Life Research Network</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33155</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank Alvarez Li, MD</last_name>
      <email>frankluandamd@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AdventHealth (Florida Hospital) - Diabetes Institute - Orlando</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Richard Pratley</last_name>
      <email>richard.pratley.md@adventhealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Atlanta Diabetes Associates (ADA)</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30318</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruce Bode</last_name>
      <email>bbode001@aol.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Louis Philipson</last_name>
      <email>l-philipson@uchicago.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Prairie Education and Research Cooperative d/b/a Central Illinois Diabetes and Clinical</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62711</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marina Russo, MD</last_name>
      <email>Marina.russo@hshs.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Cotton-O'Neil Diabetes and Endocrinology Center</name>
      <address>
        <city>Topeka</city>
        <state>Kansas</state>
        <zip>66606-28</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alan Wynne, MD</last_name>
      <email>awynne@stormontvail.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40292</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kupper Wintergerst</last_name>
      <email>kupper.wintergerst@louisville.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Joslin Diabetes Center, Harvard Medical School</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jason Gaglia</last_name>
      <email>jason.gaglia@joslin.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UBMD Physicians Group - Pediatrics - Conventus</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lucy Mastrandrea</last_name>
      <email>lmastrandrea@upa.chob.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>&quot;WakeMed Physician Practices - Pediatric Endocrinology - WakeMed Raleigh Medical Park Location&quot;</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hillary Lockemer</last_name>
      <email>hlockemer@wakemed.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania Perelman School of Medicine</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Rickels</last_name>
      <email>rickels@pennmedicine.upenn.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Serge Jabbour, MD</last_name>
      <email>serge.jabbour@jefferson.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh - UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15261</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frederico G S Toledo</last_name>
      <email>toledofs@upmc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cook Children's Endocrinology and Diabetes Program</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Thorton</last_name>
      <email>Paul.thornton@cookchildrens.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mustafa Tosur</last_name>
      <email>mustafa.tosur@bcm.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Eastern Virginia Medical School (EVMS) - Strelitz Diabetes Center</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elias Siraj, MD</last_name>
      <email>sirajes@evms.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique du Sud Luxembourg - Vivialia-Arlon</name>
      <address>
        <city>Arlon</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Weber</last_name>
      <email>eric.weber@vivalia.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Brussel (UZB)</name>
      <address>
        <city>Jette</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Corinne Debroye</last_name>
      <email>corine.debroye@uzbrussel.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>General Hospital AZ Nikolaas</name>
      <address>
        <city>Sint-Niklaas</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johannes Ruige</last_name>
      <email>johannes.ruige@aznikolaas.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aleksandre Aladashvili Clinic LLC</name>
      <address>
        <city>Tbilisi</city>
        <zip>48102</zip>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nana Kokoshvili, MD</last_name>
      <email>nanakokoshvili@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Center for Diabetes Research LTD</name>
      <address>
        <city>Tbilisi</city>
        <zip>48159</zip>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Givi Kurashvili, MD</last_name>
      <email>gkurashfili@yahoo.co.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Institute of Endocrinology LTD</name>
      <address>
        <city>Tbilisi</city>
        <zip>48159</zip>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elene Giorgadze, MD</last_name>
      <email>el_giorgadze@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tbilisi Heart and Vascular Clinic LTD</name>
      <address>
        <city>Tbilisi</city>
        <zip>48159</zip>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mariam Balakhadze, MD</last_name>
      <email>mbalakhadze@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical Center - University of Freiburg</name>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jochen Seufert</last_name>
      <email>office-seufert.med@uniklinik-freiburg.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Gessen und Marburg GmbH - Medizinische Klinik und Poliklinik III</name>
      <address>
        <city>Glessen</city>
        <zip>35392</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Linn, MD</last_name>
      <email>thomas.linn@innere.med.uni-giessen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Diabestesinstitut Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christoph Hasselacher</last_name>
      <email>c.hasslacher@diabetesinstitut-hd.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Die Praxis am Ludwigsplatz</name>
      <address>
        <city>Ludwigshafen am Rhein</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hans-Peter Kempe</last_name>
      <email>hans-peter.kempe@t-online.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut fuer Diabetes forschung in Muenster (IDFM)</name>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rose Ludger</last_name>
      <email>l.rose@diabetes-muenster.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Schwerpunktpraxis fuer Diabetes &amp; Ernaehrungsmedizin</name>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Winfried Keuthage</last_name>
      <email>keuthage@diabetes-praxis-muenster.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Soroka Medical Center</name>
      <address>
        <city>Be'er Sheva</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eli Hershkovitz</last_name>
      <email>elih@bgu.ac.il</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Schneider Children's Medical Center, Petah Tikva</name>
      <address>
        <city>Petah Tikva</city>
        <zip>4920235</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Phillip Moshe, MD</last_name>
      <email>mosheph@tauex.tau.ac.il</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tel Aviv Sourasky Medical Center</name>
      <address>
        <city>Tel Aviv-Yafo</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eldor Roy</last_name>
      <email>roye@tlvmc.gov.il</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Pediatrico G. Salesi - Centro Regionale di Diabetologia Clinica Pediatrica</name>
      <address>
        <city>Ancona</city>
        <zip>60123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valentino Cherubini, MD</last_name>
      <email>valentino.cherubini@ospedaliriuniti.marche.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria Conzorziale Policlinico di Bari</name>
      <address>
        <city>Bari</city>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesco Giorgino, MD</last_name>
      <email>f.giorgino@endo.uniba.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Università degli Studi Magna Graecia di Catanzaro, Azienda Ospedaliero-Universitaria Mater Domini</name>
      <address>
        <city>Catanzaro</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Concetta Irace</last_name>
      <email>irace@unicz.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitá degli Studi di Milano - Ospedale Luigi Saco</name>
      <address>
        <city>Milan</city>
        <zip>20157</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paolo Fiorina, MD</last_name>
      <email>paolo.fiorina@unimi.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro regionale di Diabetologia Pediatrica &quot;G. Stoppoloni&quot;, Azienda Ospedaliera Universitaria &quot;Luigi Vanvitelli&quot;</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dario Iafusco</last_name>
      <email>dario.iafusco@unicampania.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Policlinico &quot;Paolo Giaccone&quot;</name>
      <address>
        <city>Palermo</city>
        <zip>90127</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carla Giordano, MD</last_name>
      <email>cgiordan@unipa.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Università Campus Bio-Medico di Roma (UCBM) - Policlinico Universitario</name>
      <address>
        <city>Roma</city>
        <zip>00128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paolo Pozzilli, Professor</last_name>
      <email>p.pozzilli@unicampus.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) - Ospedale Pediatrico Bambino Gesu</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Riccardo Schiaffini</last_name>
      <email>riccardo.schiaffini@opbg.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universita Cattolica del Sacro Cuore - Policlinico Universitario &quot;Agostino Gemelli&quot;</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dario Pitocco</last_name>
      <email>dario.pitocco@policlinicogemelli.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>&quot;Sapienza&quot; Università di Roma- Azienda Ospedaliero Universitaria Policlinico Umberto I</name>
      <address>
        <city>Rome</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raffaella Buzzetti, MD</last_name>
      <email>raffaella.buzzetti@uniroma1.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Center of Serbia, Clinic for Endocrinology, Diabetes and Metabolic Diseases</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nebojsa Lalic, MD</last_name>
      <email>nebojsa.m.lalic@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Center of Serbia, Clinic for Endocrinology, Diabetes and Metabolic Diseases</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katarina Lalic, MD</last_name>
      <email>katarina.s.lalic@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Children's Hospital</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vera Zdravkovic</last_name>
      <email>vera.zdravkovic@udk.bg.ac.rs</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical center Kragujevac, Clinic for internal diseases, Center for endocrinology, diabetes and metabolic diseases</name>
      <address>
        <city>Kragujevac</city>
        <zip>34000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aleksandar Djukic, MD</last_name>
      <email>adjukic@sbb.rs</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Center Nis, Clinic for endocrinology</name>
      <address>
        <city>Niš</city>
        <zip>18000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Radivoj Kocic, MD</last_name>
      <email>ciricv@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Center Nis, Clinic for endocrinology</name>
      <address>
        <city>Niš</city>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Milica Pecic</last_name>
      <email>mimapesic@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Children's Hospital, University Medical Center Ljubljana</name>
      <address>
        <city>Lubiana</city>
        <country>Slovenia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tadej Battelino</last_name>
      <email>tadej.battelino@mf.uni-lj.si</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Georgia</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Serbia</country>
    <country>Slovenia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 9, 2020</study_first_submitted>
  <study_first_submitted_qc>November 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 13, 2020</study_first_posted>
  <last_update_submitted>October 22, 2021</last_update_submitted>
  <last_update_submitted_qc>October 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>type1 diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

